TwinBeech Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

TwinBeech Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,178	Closed	-$891K	–	819
2025 Q1	$891K	Buy	+7,178	New	+$936K	0.02%	504
2024 Q1	–	Sell	-67,718	Closed	-$8.33M	–	717
2023 Q4	$8.33M	Buy	+67,718	New	+$8.45M	0.13%	196
2023 Q2	–	Sell	-16,282	Closed	-$2.38M	–	737
2023 Q1	$2.38M	Buy	+16,282	New	+$2.41M	0.05%	351
2022 Q3	–	Sell	-7,787	Closed	-$1.22M	–	720
2022 Q2	$1.22M	Buy	+7,787	New	+$1.2M	0.05%	294
2022 Q1	–	Sell	-15,549	Closed	-$1.98M	–	621
2021 Q4	$1.98M	Buy	+15,549	New	+$2.04M	0.11%	233
2021 Q2	–	Sell	-7,150	Closed	-$1.18M	–	548
2021 Q1	$1.18M	Buy	+7,150	New	+$1.18M	0.17%	175

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TwinBeech Capital's JAZZ Position: Q2 2025 in Review

TwinBeech Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 7,178 shares — an estimated $891K sold.

TwinBeech Capital first reported a position in JAZZ in Q1 2021 and held it in 6 quarters. The position peaked at $8.33M in Q4 2023. 502 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

TwinBeech Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 7,178 Jazz Pharmaceuticals shares in Q2 2025, an estimated $891K.
TwinBeech Capital first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 6 quarters.
TwinBeech Capital's Jazz Pharmaceuticals position peaked at $8.33M in Q4 2023.
502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.